Sarkis Serge Messerlian

OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.

Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ.

Amnis Corp. provides cell imaging and instrument development, manufacturing and marketing services. The Company's ImageStreamX and FlowSight imaging flow cytometers combine the speed and sensitivity of flow cytometry with the power of digital microscopy serving a broad spectrum of Life Sciences research market needs. The company was founded by David A. Basiji, William E. Ortyn and Harold H. Kawaguchi in 1999 and is headquartered in Seattle, WA.

Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA.

Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH.

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA.

The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA.

Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY.

MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN.

Kumquat Biosciences, Inc. provides biotechnology services. The company was founded by Yi Liu and Pingda Ren and is headquartered in San Diego, CA.

Part of Frontera Therapeutics, Inc., Frontera Therapeutics (HK) Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The company was founded by Yong Dai and Yong Dai has been the CEO since incorporation.

Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation.

Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation.

Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters.

Gwynant Therapeutics develops new small molecules for oncology targets.

Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation.

Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation.

Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation.

Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA.